Identification and functional characterization of potential oncofetal targets in human hepatocellular carcinoma

  • STAR Protoc. 2022 Dec 16;3(4):101921. doi: 10.1016/j.xpro.2022.101921.
Mei-Mei Li  1 ,  Fan-En Kong  1 ,  Guang-Meng Li  2 ,  Yi-Ti He  1 ,  Xiao-Feng Zhang  3 ,  Cheng-Yang Zhang  1 ,  Jie-Kai Liang  4 ,  Xin-Yuan Guan  5 ,  Ning-Fang Ma  1 ,  Mao-Bin Xie  6 ,  Ming Liu  7
Affiliations
  • 1. Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou 510095, China; Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou Medical University, Xinzao, Panyu District, Guangzhou 511436, China.
  • 2. The Second Affiliated Hospital, The State Key Laboratory of Respiratory Disease, Provincial Key Laboratory of Allergy & Clinical Immunology, Guangzhou Medical University, Guangzhou 510260, China.
  • 3. Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510623, China.
  • 4. The Third Clinical School of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 511436, China.
  • 5. Department of Clinical Oncology, State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, China.
  • 6. The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Biomedical Engineering, Guangzhou Medical University, Guangzhou 511436, China. Electronic address: [email protected].
  • 7. Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou 510095, China; Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou Medical University, Xinzao, Panyu District, Guangzhou 511436, China. Electronic address: [email protected].
PMID: 36595904 DOI: 10.1016/j.xpro.2022.101921
Abstract

Here, we present a detailed protocol for the identification of potential oncofetal targets for hepatocellular carcinoma (HCC) patients through a hepatocyte differentiation model and a sorafenib refractory cell-line-derived xenograft model. We describe the procedures of tumor sphere formation, Organoid generation, and subcutaneous tumor formation for functional studies. We then detail the procedures of immunohistochemistry and immunofluorescence for examination of changes in lineage-specific markers. Finally, we describe the development of antibody-based therapeutics targeting tumor lineage plasticity in HCC. For complete details on the use and execution of this protocol, please refer to Kong et al. (2021).1.

Keywords
Cancer; Health Sciences; Model Organisms; Organoids.
Products